<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1128">
  <stage>Registered</stage>
  <submitdate>11/04/2006</submitdate>
  <approvaldate>11/04/2006</approvaldate>
  <nctid>NCT00314132</nctid>
  <trial_identification>
    <studytitle>Safety Study of ChimeriVax-JE Vaccine to Prevent Japanese Encephalitis.</studytitle>
    <scientifictitle>Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax-JE)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>H-040-010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Encephalitis</healthcondition>
    <healthcondition>Japanese Encephalitis</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - ChimeriVax-JE, Japanese Encephalitis vaccine
Other interventions - 0.9% Saline

Placebo Comparator: Placebo - All subjects received a single injection of placebo on Day 0.

Experimental: ChimeriVax JE 4 log10 PFU Vaccine - All participants received a single injection of ChimeriVax JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.


Other interventions: ChimeriVax-JE, Japanese Encephalitis vaccine
0.5 mL, Subcutaneous

Other interventions: 0.9% Saline
0.5 mL, Subcutaneous

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants Reporting Treatment Related Adverse Events Post Vaccination With Either ChimeriVax-JE or a Placebo - Adverse events were collected by means of diary cards and scripted interviews. All adverse events reporting was considered "actively solicited" through Day 30.</outcome>
      <timepoint>Day 0 up to 30 days post-vaccination</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Participants Reporting Treatment Emergent Local Adverse Reactions and Treatment Emergent Systemic Reactions Post-vaccination With Either ChimeriVax-JE or a Placebo - Treatment emergent local adverse reactions: Injection Site Pain, Itching, Erythema, Swelling, Induration, Skin Rash, and others as reported.
Treatment emergent systemic reactions: Malaise, Headache, Myalgia, Feeling Hot, Chills, Fatigue, Dyspnea, Wheezing, Nausea, Vomiting, Diarrhea, Abdominal Pain and others as reported.</outcome>
      <timepoint>Day 0 up to 30 days post-vaccination</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Informed consent obtained from the subject.

          -  Aged 18 years or above at screening.

          -  In good general health

          -  Subject available for the study duration

          -  For female subjects (of child bearing potential) a negative pregnancy tests at
             Screening and Day 0.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  A history of vaccination against or infection with JE.

          -  Known or suspected immunodeficiency, use of immunosuppressive or antineoplastic drugs.

          -  History of thymoma, thymic surgery (removal) or myasthenia gravis.

          -  Clinically significant abnormalities on laboratory assessment

          -  Anaphylaxis or other serious adverse reactions characterised by urticaria or
             angioedema to foods, Hymenoptera (bee family) stings, or drugs including vaccines).

          -  Transfusion of blood or treatment with any blood product, including intramuscular or
             intravenous serum globulin within six months of the Screening Visit or up to Day 30.

          -  Administration of another vaccine or antiviral within 30 days preceding the Screening
             visit or up to Day 30.

          -  Physical examination indicating any clinically significant medical condition.

          -  Oral temperature &gt;38°C (100.4°F) or acute illness within 3 days prior to inoculation.

          -  Intention to travel out of the area for an extended period that may affect the
             subjects ability to attend clinic visits prior to the study visit up to Day 30.

          -  Seropositive to hepatitis C virus (HCV) or HIV or positive for Hepatitis B Surface
             Antigen.

          -  Lactation or intended pregnancy in female subjects.

          -  Excessive alcohol consumption, drug abuse, significant psychiatric illness.

          -  A known or suspected physiological or structural condition that compromises the
             integrity of the blood-brain barrier (e.g. cerebrovascular disease, multiple
             sclerosis, trauma, infection, inflammation of the brain or meninges).

          -  Participation in another clinical study within 30 days of the screening visit for this
             study.

          -  Employee of the study site, Sponsor or Clinical Research Organization (CRO) involved
             with the management of the study.

          -  Any other reasons, which in the investigator's opinion, makes the subject unsuitable
             to participate in the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>2004</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Darlinghurst</hospital>
    <hospital> - Enoggera</hospital>
    <hospital> - Heidelbeg West</hospital>
    <hospital> - Kippa-Ring</hospital>
    <hospital> - Mill Park</hospital>
    <hospital> - Toorak Gardens</hospital>
    <postcode>NSW 2010 - Darlinghurst</postcode>
    <postcode>QLD 4051 - Enoggera</postcode>
    <postcode>VIC 3081 - Heidelbeg West</postcode>
    <postcode>QLD 4021 - Kippa-Ring</postcode>
    <postcode>VIC 3082 - Mill Park</postcode>
    <postcode>SA 5056 - Toorak Gardens</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess whether ChimeriVax JE vaccine (a new vaccine to be
      used for vaccination against Japanese encephalitis) is safe and well tolerated when compared
      to placebo (dummy) vaccination.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00314132</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Steven G Hull, MD</name>
      <address>Vince and Associates Clinical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>